Collectively, this study shows that functional outcome based biology approach can address the complexity of the tumor microenvironment by understanding the dynamic nature of neoplasms in terms of response outcome in clinically aggressive cancers such as CRC, which are otherwise confirmed as wt for validated KRAS mutations. The gene discussed is KRAS; the disease is colorectal carcinoma.